Cue Biopharma Shares Surge 40% Ahead of Key Immunotherapy Presentations
October 04, 2024 at 4:42 pm - by Editor Prism MarketView
Cue Biopharma (NASDAQ: CUE) shares surged nearly 40% after announcing plans to present data on its Immuno-STAT drug candidates, CUE-101 and CUE-102, at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10.
The company will deliver an oral presentation on the Phase 1 study of CUE-101 for HPV16+ head and neck squamous cell cancer and a poster presentation on the Phase 1 trial of CUE-102 in patients with WT1-positive recurrent/metastatic cancers.
Cue Biopharma, a clinical-stage biotech, specializes in developing biologics to modulate disease-specific T cells directly in the patient’s body using its proprietary Immuno-STAT™ platform.
